Skip to main content
Premium Trial:

Request an Annual Quote

This Heart's Not for Sale

Premium

Framingham Genomics Medicine, a company founded with $21 million in venture capital and led in part by Fred Ledley, former CEO and president of Variagenics, plans to close its doors. Formed to organize data from the 52-year-old Framingham Heart Study, the company was forced to disband after Boston University and the National Heart, Lung, and Blood Institute denied it access to the data.

The conflict between the study’s insistence on free academic access and the company’s need for profitability led to an impasse between the groups, says Kevin Carleton, a spokesman for BU. The for-profit closed its doors when academia won out.

That doesn’t mean that BU’s original idea for data organization has been totally thwarted. Study data has not been assembled in a way that facilitates “aggressive analysis,” says Carleton. “Much of [the data] was collected in the pre-computer era,” he explains. In a letter to some 6,000 study subjects, Claude Lenfant, director of NHLBI, and Aram Chobanian, dean of BU’s School of Medicine, write that the effort will continue “through more traditional avenues, such as grants, contracts, and donations.”

— Marian Moser Jones

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.